CT224 / Chantibody Therapeutics - LARVOL DELTA

CT224: a novel biparatopic VHH-based CDH17×CD3 T cell engager optimized for safety and efficacy in colorectal cancer (SITC 2025) - "Furthermore, CT224 demonstrated good developability characteristics, including high expression yield and purification purity, low polyreactivity, and excellent thermal stability—supporting its advancement toward clinical development.Conclusions CT224, a novel biparatopic VHH-based CDH17×CD3 TCE, combines potent antitumor efficacy with a favorable safety profile and small molecular size for improved tumor penetration—addressing key limitations of TCEs in solid tumors. Its cross-species reactivity, favorable pharmacokinetics, and strong developability profile support ongoing preclinical development and potential clinical translation as a first-in-class TCE for CRC."

Clinical • Colorectal Cancer • Oncology • Solid Tumor • CDH17